Alnylam Pharmaceuticals (ALNY) EBIT Margin (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly EBIT Margin came in at 17.93% in Q2 2026, up 2002.0% YoY from 0.85% in Q2 2025, and down 22.11% on a QoQ basis from 23.02% in Q1 2026.
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) EBIT Margin (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of EBIT Margin data on file, last reported at 17.93% in Q2 2026.
- Quarterly EBIT Margin rose 2002.0% year-over-year to 17.93% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 20.81% (up 3031.0% YoY) and the FY2025 annual result came in at 13.51%, up 2137.0% from the prior year.
- EBIT Margin fell to 17.93% in Q2 2026, from 23.02% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 60.26% in Q1 2025 to a low of 97.63% in Q3 2022.
- A 5-year average of 17.72% and a median of 12.07% in 2024 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2023 — EBIT Margin jumped 12612 bps — and 2024, when it sank 4385 bps.
- Tracing ALNY's EBIT Margin over 5 years: stood at 56.3% in 2022, then surged by 53 bps to 26.47% in 2023, then surged by 33 bps to 17.73% in 2024, then soared by 168 bps to 12.01% in 2025, then surged by 49 bps to 17.93% in 2026.
- The last three EBIT Margin figures came in at 17.93% (Q2 2026), 23.02% (Q1 2026), and 12.01% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | 41.69% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 17.93% |
| Mar 31, 2026 | 23.02% |
| Dec 31, 2025 | 12.01% |
| Sep 30, 2025 | 29.46% |
| Jun 30, 2025 | -2.09% |
| Mar 31, 2025 | 60.26% |
| Dec 31, 2024 | -17.73% |
| Sep 30, 2024 | -15.35% |
| Jun 30, 2024 | 7.37% |
| Mar 31, 2024 | -8.79% |
| Dec 31, 2023 | -26.47% |
| Sep 30, 2023 | 28.50% |
| Jun 30, 2023 | -72.10% |
| Mar 31, 2023 | -46.92% |
| Dec 31, 2022 | -56.30% |
| Sep 30, 2022 | -97.63% |
| Jun 30, 2022 | -85.26% |
| Mar 31, 2022 | -68.80% |
| Dec 31, 2021 | -75.26% |
| Sep 30, 2021 | -96.83% |